Allergan False Marking Case Survives Dismissal Bid
A federal judge has denied Allergan Inc.'s motion to dismiss a suit accusing the health care company of marking its Restasis prescription eye drop product with two expired patents....To view the full article, register now.
Already a subscriber? Click here to view full article